Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

665P - Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab + axitinib (A + Ax) or sunitinib (S): Results from JAVELIN Renal 101

Date

16 Sep 2021

Session

ePoster Display

Topics

Clinical Research;  Immunotherapy

Tumour Site

Renal Cell Cancer

Presenters

Marc-Oliver Grimm

Citation

Annals of Oncology (2021) 32 (suppl_5): S678-S724. 10.1016/annonc/annonc675

Authors

M. Grimm1, M. Oya2, T.K. Choueiri3, M. Schmidinger4, D.I. Quinn5, G. Gravis Mescam6, E. Verzoni7, A.J.M. Van den Eertwegh8, A. di Pietro9, M. Mariani10, J. Wang11, D. Thomaidou12, L. Albiges13

Author affiliations

  • 1 Department Of Urology, University Hospital of Jena, 07747 - Jena/DE
  • 2 Department Of Urology, Keio University School of Medicine, 160-8582 - Tokyo/JP
  • 3 The Lank Center For Genitourinary Oncology, Dana-Farber Cancer Institute, 02215 - Boston/US
  • 4 Department Of Urology, Medical University of Vienna, Austria, 1090 - Vienna/AT
  • 5 Division Of Oncology, USC Keck School of Medicine, 90033 - Los Angeles/US
  • 6 Department Of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille University, Inserm, CNRS, CRCM, 13009 - Marseille/FR
  • 7 Department Of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 - Milan/IT
  • 8 Department Of Medical Oncology, VU University Medical Center, 1081 HV - Amsterdam/NL
  • 9 Immuno-oncology, Pfizer Italia S.r.l., 20152 - Milan/IT
  • 10 Clinical Development & Operation, Pfizer Italia S.r.l., 20152 - Milan/IT
  • 11 Global Product Development, Pfizer, 02139 - Cambridge/US
  • 12 Global Medical Affairs, Pfizer, 154 51 - Athens/GR
  • 13 Gustave Roussy Cancer Campus, University of Paris Saclay, 94 800 - Villejuif/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 665P

Background

Cytoreductive nephrectomy (neph) remains controversial in the management of patients (pts) with mRCC; the role of prior neph in pts treated with immune checkpoint inhibitor remains unknown. In this extended follow-up analysis of the phase III JAVELIN Renal 101 trial (NCT02684006), we assessed the role of prior neph in pts with mRCC presenting with synchronous metastases at the time of diagnosis and treated with A + Ax or S.

Methods

Efficacy outcomes were assessed from the third interim analysis in pts with mRCC who presented with M1 disease at the time of diagnosis and had undergone prior neph or no neph in the A + Ax and S arms. Multivariate Cox regression analyses were used to assess hazard ratios for overall survival (OS) and progression-free survival (PFS; investigator assessment per RECIST 1.1). Logistic regression method was used to obtain the odds ratio for objective response (investigator assessment per RECIST 1.1).

Results

412 of 886 pts in JAVELIN Renal 101 presented with M1 disease at diagnosis. Of these pts, 126 (A + Ax) and 147 (S) had undergone prior neph and 72 (A + Ax) and 67 (S) had no neph. Compared with the neph group, a higher proportion of pts in the no-neph group were older (42% vs 32% were ≥65 years), had impaired PS (ECOG PS 1, 54% vs 40%), and had poor prognosis (40% vs 16% by IMDC criteria); fewer pts had PD-L1+ tumors (40% vs 77%). To assess the impact of neph, these parameters were adjusted in the multivariate model. Post hoc analyses showed that in the A + Ax arm, OS and confirmed objective response were significantly improved in pts with neph vs no neph; however, no differences were observed in the S arm (Table). PFS was numerically longer in pts with neph vs no neph in the A + Ax arm but not in the S arm.

Conclusions

Pts who presented with M1 disease at the time of diagnosis and had undergone prior neph had superior efficacy outcomes vs no neph with A + Ax but not with S. Table: 665P

Multivariate analysis Neph vs no neph
A + Ax S
Hazard ratio for OS (95% CI) 0.593 (0.379-0.930) 0.859 (0.551-1.341)
Hazard ratio for PFS (95% CI) 0.785 (0.531-1.161) 1.146 (0.773-1.699)
Odds ratio for objective response (95% CI) 2.669 (1.315-5.414) 2.018 (0.824-4.941)

Clinical trial identification

NCT02684006.

Editorial acknowledgement

Medical writing support was provided by Kakoli Parai of ClinicalThinking and funded by Pfizer and Merck KGaA, Darmstadt, Germany.

Legal entity responsible for the study

Pfizer and Merck KGaA, Darmstadt, Germany.

Funding

Pfizer and Merck KGaA, Darmstadt, Germany.

Disclosure

M. Grimm: Financial Interests, Personal, Other, Honoraria: Astellas Pharma; Financial Interests, Personal, Other, Honoraria: AstraZeneca; Financial Interests, Personal, Other, Honoraria: Bristol-Myers Squibb; Financial Interests, Personal, Other, Honoraria: Merck Sharp & Dohme; Financial Interests, Personal, Other, Honoraria: Pfizer; Financial Interests, Personal, Other, Honoraria: Ipsen; Financial Interests, Personal, Other, Honoraria: Merck Serono; Financial Interests, Personal, Other, Honoraria: EUSA Pharma; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: Bristol-Myers Squibb; Financial Interests, Personal, Advisory Role: Ipsen; Financial Interests, Personal, Advisory Role: Merck Sharp & Dohme; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: Astellas Pharma; Financial Interests, Personal, Advisory Role: EUSA Pharma; Financial Interests, Personal, Advisory Role: Merck Serono; Financial Interests, Personal, Advisory Role: Roche Pharma AG; Financial Interests, Personal, Advisory Role: Takeda; Financial Interests, Personal, Advisory Role: Eisai; Financial Interests, Institutional, Research Grant: Bristol-Myers Squibb; Financial Interests, Institutional, Research Grant: Intuitive Surgical; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Bristol-Myers Squibb; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Merck Serono. M. Oya: Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: Bayer; Financial Interests, Personal, Invited Speaker: Ono; Financial Interests, Personal, Invited Speaker: Bristol-Myers Squibb; Financial Interests, Personal, Invited Speaker: Takeda; Financial Interests, Personal, Invited Speaker: Merck Sharp & Dohme. T.K. Choueiri: Financial Interests, Personal, Stocks/Shares: Pionyr; Financial Interests, Personal, Stocks/Shares: Tempest Therapeutics; Financial Interests, Personal, Other, Honoraria: Alexion Pharmaceuticals; Financial Interests, Personal, Other, Honoraria: Alligent; Financial Interests, Personal, Other, Honoraria: Analysis Group; Financial Interests, Personal, Other, Honoraria: ASCO; Financial Interests, Personal, Other, Honoraria: AstraZeneca; Financial Interests, Personal, Other, Honoraria: Bayer; Financial Interests, Personal, Other, Honoraria: Bristol-Myers Squibb; Financial Interests, Personal, Other, Honoraria: Cerulean Pharma; Financial Interests, Personal, Other, Honoraria: Clinical Care Options; Financial Interests, Personal, Other, Honoraria: Corvus Pharmaceuticals; Financial Interests, Personal, Other, Honoraria: Eisai; Financial Interests, Personal, Other, Honoraria: EMD Serono; Financial Interests, Personal, Other, Honoraria: Exelixis; Financial Interests, Personal, Other, Honoraria: Foundation Medicine; Financial Interests, Personal, Other, Honoraria: Genetech/Roche; Financial Interests, Personal, Other, Honoraria: GlaxoSmithKline; Financial Interests, Personal, Other, Honoraria: Harborside Press; Financial Interests, Personal, Other, Honoraria: Heron; Financial Interests, Personal, Other, Honoraria: Ipsen; Financial Interests, Personal, Other, Honoraria: Kidney Cancer Association; Financial Interests, Personal, Other, Honoraria: Lancet Oncology; Financial Interests, Personal, Other, Honoraria: Lilly; Financial Interests, Personal, Other, Honoraria: Lpath; Financial Interests, Personal, Other, Honoraria: Merck Sharp & Dohme; Financial Interests, Personal, Other, Honoraria: Michael J. Hennessy Associates; Financial Interests, Personal, Other, Honoraria: Navinata Health; Financial Interests, Personal, Other, Honoraria: NCCN; Financial Interests, Personal, Other, Honoraria: Novartis; Financial Interests, Personal, Other, Honoraria: Peloton Therapeutics; Financial Interests, Personal, Other, Honoraria: Pfizer; Financial Interests, Personal, Other, Honoraria: PlatformQ Health; Financial Interests, Personal, Other, Honoraria: Prometheus; Financial Interests, Personal, Other, Honoraria: Sanofi/Aventis; Financial Interests, Personal, Other, Honoraria: New England Journal of Medicine; Financial Interests, Personal, Advisory Role: Alexion Pharmaceuticals; Financial Interests, Personal, Advisory Role: Alligent; Financial Interests, Personal, Advisory Role: Analysis Group; Financial Interests, Personal, Advisory Role: ASCO; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: Bayer; Financial Interests, Personal, Advisory Role: Bristol-Myers Squibb; Financial Interests, Personal, Advisory Role: Cerulean Pharma; Financial Interests, Personal, Advisory Role: Clinical Care Options; Financial Interests, Personal, Advisory Role: Corvus Pharmaceuticals; Financial Interests, Personal, Advisory Role: Eisai; Financial Interests, Personal, Advisory Role: EMD Serono; Financial Interests, Personal, Advisory Role: ESMO; Financial Interests, Personal, Advisory Role: Exelixis; Financial Interests, Personal, Advisory Role: Foundation Medicine; Financial Interests, Personal, Advisory Role: GlaxoSmithKline; Financial Interests, Personal, Advisory Role: Harborside Press; Financial Interests, Personal, Advisory Role: Heron; Financial Interests, Personal, Advisory Role: Ipsen; Financial Interests, Personal, Advisory Role: Kidney Cancer Association; Financial Interests, Personal, Advisory Role: Lancet Oncology; Financial Interests, Personal, Advisory Role: Lilly; Financial Interests, Personal, Advisory Role: Lpath; Financial Interests, Personal, Advisory Role: Merck Sharp & Dohme; Financial Interests, Personal, Advisory Role: Michael J. Hennessy Associates; Financial Interests, Personal, Advisory Role: Navinata Health; Financial Interests, Personal, Advisory Role: NCCN; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Peloton Therapeutics; Financial Interests, Personal, Leadership Role: Pfizer; Financial Interests, Personal, Leadership Role: PlatformQ Health; Financial Interests, Personal, Leadership Role: Prometheus; Financial Interests, Personal, Advisory Role: Roche/Genentech; Financial Interests, Personal, Advisory Role: Sanofi/Aventis; Financial Interests, Personal, Advisory Role: New England Journal of Medicine; Financial Interests, Institutional, Research Grant: Agensys; Financial Interests, Institutional, Research Grant: Analysis Group; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Research Grant: Bayer; Financial Interests, Institutional, Research Grant: Bristol-Myers Squibb; Financial Interests, Institutional, Research Grant: Calithera Biosciences; Financial Interests, Institutional, Research Grant: Celldex; Financial Interests, Institutional, Research Grant: Cerulean Pharma; Financial Interests, Institutional, Research Grant: Congressionally Directed Medical Research Programs (DOD); Financial Interests, Institutional, Research Grant: Corvus Pharmaceuticals; Financial Interests, Institutional, Research Grant: Eisai; Financial Interests, Institutional, Research Grant: Exelixis; Financial Interests, Institutional, Research Grant: Foundation Medicine; Financial Interests, Institutional, Research Grant: Gateway for Cancer Research; Financial Interests, Institutional, Research Grant: GlaxoSmithKline; Financial Interests, Institutional, Research Grant: Ipsen; Financial Interests, Institutional, Research Grant: Merck Sharp & Dohme; Financial Interests, Institutional, Research Grant: NCI; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Institutional, Research Grant: Peloton Therapeutics; Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Institutional, Research Grant: Prometheus; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Institutional, Research Grant: Roche/Genentech; Financial Interests, Institutional, Research Grant: Seattle Genetics/Astellas; Financial Interests, Institutional, Research Grant: Takeda; Financial Interests, Institutional, Research Grant: Tracon Pharmaceuticals; Financial Interests, Personal, Other, owns patents, royalties, or other intellectual property: PCT/US2018/058430, PCT/US2018/12209; Financial Interests, Personal, Other, Honoraria: UpToDate. M. Schmidinger: Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Bristol-Myers Squibb; Financial Interests, Personal, Advisory Role: Merck KGaA, Darmstadt, Germany; Financial Interests, Personal, Advisory Role: Merck Sharp & Dohme; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: EUSA; Financial Interests, Personal, Advisory Role: Eisai; Financial Interests, Personal, Advisory Role: Ipsen; Financial Interests, Personal, Advisory Role: Exelixis; Financial Interests, Personal, Advisory Role: Alkermes plc; Financial Interests, Personal, Other, Honoraria for Lectures: Bristol-Myers Squibb; Financial Interests, Personal, Other, Honoraria for Lectures: Merck KGaA, Darmstadt, Germany; Financial Interests, Personal, Other, Honoraria for Lectures: Merck Sharp & Dohme; Financial Interests, Personal, Other, Honoraria for Lectures: Pfizer; Financial Interests, Personal, Other, Honoraria for Lectures: EUSA; Financial Interests, Personal, Other, Honoraria for Lectures: Eisai; Financial Interests, Personal, Other, Honoraria for Lectures: Ipsen; Financial Interests, Personal, Other, Honoraria for Lectures: Exelixis. D.I. Quinn: Financial Interests, Personal, Invited Speaker, Educational lectures: Astellas; Financial Interests, Personal, Advisory Board, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board, Advisory Board: BMS; Financial Interests, Personal, Advisory Board, Advisory Board: Genentech; Financial Interests, Personal, Advisory Board, Advisory Board: Roche; Financial Interests, Personal, Advisory Board, Advisory Board: Merck; Financial Interests, Personal, Advisory Board, Advisory Board: Exelixis; Financial Interests, Personal, Advisory Board, Advisory Board: EMD Serono; Financial Interests, Personal, Advisory Board, Advisory Board: Seattle Genetics; Financial Interests, Personal, Invited Speaker, Educational lectures and Advisory Board: Pfizer; Financial Interests, Personal, Other, Data Safety Monitoring: Eisai; Financial Interests, Institutional, Invited Speaker, phase 2 study, phase 3 study: Pfizer; Financial Interests, Institutional, Funding, phase 2 study: Merck; Financial Interests, Institutional, Funding, phase 2 trial: Genentech; Financial Interests, Personal and Institutional, Invited Speaker, Coordination of international phase 2/3 trial: Bayer. G. Gravis Mescam: Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Janssen Oncology; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Bristol-Myers Squibb; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Astellas Pharma; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Pfizer; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Ipsen; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Sanofi. E. Verzoni: Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Advisory Role: Merck KGaA; Financial Interests, Personal, Advisory Role: Ipsen. A.J.M. Van den Eertwegh: Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Institutional, Research Grant: Sanofi; Financial Interests, Institutional, Research Grant: TEVA; Financial Interests, Personal and Institutional, Advisory Role: Bristol-Myers Squibb; Financial Interests, Personal and Institutional, Advisory Role: Merck Sharp & Dohme; Financial Interests, Personal and Institutional, Advisory Role: AMGEN; Financial Interests, Personal and Institutional, Advisory Role: Pfizer; Financial Interests, Personal and Institutional, Advisory Role: Merck & Co.; Financial Interests, Personal and Institutional, Advisory Role: Novartis; Financial Interests, Personal and Institutional, Advisory Role: Ipsen; Financial Interests, Personal and Institutional, Advisory Role: Pierre Fabre; Financial Interests, Personal and Institutional, Advisory Role: Eisai; Financial Interests, Personal, Speaker’s Bureau: Bristol-Myers Squibb. A. di Pietro: Financial Interests, Personal, Full or part-time Employment: Pfizer; Financial Interests, Personal, Stocks/Shares: Pfizer. M. Mariani: Financial Interests, Personal, Full or part-time Employment: Pfizer; Financial Interests, Personal, Stocks/Shares: Pfizer. J. Wang: Financial Interests, Personal, Full or part-time Employment: Pfizer. D. Thomaidou: Financial Interests, Personal, Full or part-time Employment: Pfizer; Financial Interests, Personal, Full or part-time Employment: Pfizer. L. Albiges: Financial Interests, Institutional, Research Grant: Bristol-Myers Squibb; Financial Interests, Institutional, Advisory Role: Astellas; Financial Interests, Institutional, Advisory Role: AstraZeneca; Financial Interests, Institutional, Advisory Role: Bellerophon; Financial Interests, Institutional, Advisory Role: Bristol-Myers Squibb; Financial Interests, Institutional, Advisory Role: Corvus Pharmaceuticals; Financial Interests, Institutional, Advisory Role: Ipsen; Financial Interests, Institutional, Advisory Role: Janssen; Financial Interests, Institutional, Advisory Role: Merck & Co.; Financial Interests, Institutional, Advisory Role: Merck Sharp & Dohme; Financial Interests, Institutional, Advisory Role: Novartis; Financial Interests, Institutional, Advisory Role: Pfizer; Financial Interests, Institutional, Advisory Role: Springer Healthcare. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.